Cover Image
市場調查報告書

化療誘發性噁心和嘔吐(CINV) - 開發中產品分析

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 245963
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
化療誘發性噁心和嘔吐(CINV) - 開發中產品分析 Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017
出版日期: 2017年03月08日 內容資訊: 英文 88 Pages
簡介

化療誘發性噁心和嘔吐(CINV)是化療所引起的心律上升、發汗、暈眩、唾液增加等噁心嘔吐的症狀,發病要素一般認為是年齡、藥物、給藥、給藥行程及給藥途徑等。

本報告提供化療誘發性噁心和嘔吐(CINV)之治療藥開發情形調查分析,提供您開發中產品概要、臨床實驗的各階段產品概要、主要企業簡介、藥物簡介、開發中產品的最新趨勢、最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

化療誘發性噁心和嘔吐(CINV)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

治療藥的開發企業

  • Kyowa Hakko Kirin
  • BioDelivery Sciences International, Inc.
  • Heron Therapeutics, Inc.
  • Suda Ltd
  • Aphios Corporation
  • Genovate Biotechnology Co., LTD.
  • Teikoku Pharma USA, Inc.
  • SymBio Pharmaceuticals Limited
  • INSYS Therapeutics, Inc.
  • Helsinn Healthcare S.A.
  • 新日本化學
  • Acacia Pharma Ltd.
  • Helsinn Holding S.A.
  • RedHill Biopharma Ltd.
  • Tesaro, Inc.

治療藥的評估

  • 單獨療法的產品
  • 聯合治療的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • granisetron - Drug Profile
  • palonosetron hydrochloride - Drug Profile
  • (netupitant + palonosetron) - Drug Profile
  • rolapitant hydrochloride - Drug Profile
  • granisetron - Drug Profile
  • granisetron - Drug Profile
  • granisetron - Drug Profile
  • ondansetron hydrochloride CR - Drug Profile
  • (netupitant + palonosetron) - Drug Profile
  • granisetron - Drug Profile
  • granisetron - Drug Profile
  • dronabinol - Drug Profile
  • rolapitant hydrochloride - Drug Profile
  • granisetron - Drug Profile
  • (netupitant + palonosetron) - Drug Profile
  • APD-403 - Drug Profile
  • granisetron - Drug Profile
  • APD-421 - Drug Profile
  • ondansetron hydrochloride - Drug Profile
  • granisetron - Drug Profile
  • granisetron - Drug Profile
  • dronabinol - Drug Profile
  • TPW-146 - Drug Profile
  • ondansetron hydrochloride - Drug Profile
  • granisetron - Drug Profile

開發中產品的最新趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 關註資訊和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9014IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline landscape.

Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapid heart rate, sweating, dizziness and increased saliva. Risk factors include age, drug, dose, schedule of administration and route.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 3, 4, 2, 1, 9, 2 and 1 respectively.

Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Nausea and Vomiting (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Nausea and Vomiting (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chemotherapy Induced Nausea and Vomiting - Overview
  • Chemotherapy Induced Nausea and Vomiting - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development
    • Acacia Pharma Ltd
    • Aphios Corp
    • Astellas Pharma Inc
    • Camurus AB
    • Daewoong Pharmaceutical Co Ltd
    • Heron Therapeutics Inc
    • INSYS Therapeutics Inc
    • Kyowa Hakko Kirin Co Ltd
    • MannKind Corp
    • Medlab Clinical Ltd
    • Nemus Bioscience Inc
    • RedHill Biopharma Ltd
    • Serina Therapeutics Inc
    • SoluBest Ltd
    • Suda Ltd
    • Tesaro Inc
    • Therapix Biosciences Ltd
  • Chemotherapy Induced Nausea and Vomiting - Drug Profiles
    • (netupitant + palonosetron hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (palonosetron hydrochloride + Pro-netupitant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APD-403 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aprepitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aprepitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aprepitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cannabis CINV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dronabinol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FK-886 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fosnetupitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • granisetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • granisetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • granisetron hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LPI-1504 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LPI-1505 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NB-1222 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NB-2111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palmidrol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palonosetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rolapitant hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SER-232 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Zindol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chemotherapy Induced Nausea and Vomiting - Dormant Projects
  • Chemotherapy Induced Nausea and Vomiting - Discontinued Products
  • Chemotherapy Induced Nausea and Vomiting - Product Development Milestones
    • Featured News & Press Releases
      • Feb 27, 2017: TESARO Receives Positive CHMP Opinion for VARUBY
      • Feb 23, 2017: Tesaro Receives CHMP Positive Opinion for Varuby (rolapitant)
      • Jan 12, 2017: Heron Announces Submission of CINVANTI NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
      • Jan 11, 2017: TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA
      • Oct 27, 2016: Mundipharma Launches Step-change Cancer Care Medicine Akynzeo in Singapore
      • Sep 06, 2016: TESARO to present data on Rolapitant at the 2016 European Society for Medical Oncology Annual Meeting
      • Jun 23, 2016: TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer
      • Jun 04, 2016: TESARO Provides Update on Rolapitant IV at ASCO Investor Briefing
      • May 18, 2016: TESARO Announces Two Abstracts on (VARUBI) Rolapitant to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting
      • Apr 12, 2016: Suda Granted Canadian Patent For Sud-002 Oral Spray To Treat Nausea & Vomiting
      • Mar 23, 2016: TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency
      • Mar 14, 2016: TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration
      • Feb 01, 2016: Biologics Announces New Oncology Partnership
      • Dec 15, 2015: Swissmedic Approves Akynzeo (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting in Switzerland
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corp, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Astellas Pharma Inc, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Camurus AB, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Heron Therapeutics Inc, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by INSYS Therapeutics Inc, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by MannKind Corp, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Medlab Clinical Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Nemus Bioscience Inc, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Serina Therapeutics Inc, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Tesaro Inc, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Therapix Biosciences Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top